Proteomic profiles of patients suffering from subarachnoid
hemorrhage

a 2025

Proteomic profiles of patients suffering from subarachnoid hemorrhage

SMRČKA, Martin; Ondřej NAVRÁTIL; Jolana LIPKOVÁ; Michal JURAJDA; Zbyněk ZDRÁHAL et al.

Základní údaje

Originální název

Proteomic profiles of patients suffering from subarachnoid hemorrhage

Autoři

SMRČKA, Martin; Ondřej NAVRÁTIL; Jolana LIPKOVÁ ; Michal JURAJDA ; Zbyněk ZDRÁHAL; David POTĚŠIL; Michal KÝR a Kamil ĎURIŠ

Vydání

EANS2025 Vienna Congress, 2025

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30212 Surgery

Stát vydavatele

Rakousko

Utajení

není předmětem státního či obchodního tajemství

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00142696

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

subarachnoid hemorrhage; IL-6; inflammation; proteomics; biomarkers

Příznaky

Mezinárodní význam

Změněno: 25. 11. 2025 14:19, Mgr. Tereza Miškechová

Anotace

V originále

Background Inflammation is an important contributor to early brain injury after subarachnoid hemorrhage (SAH). IL-6 represents the most frequently studied marker of SAH-associated inflammation. However, IL-6 levels after SAH are highly variable, and therefore, it is not possible to define diagnostically relevant threshold levels. Our project aims to identify biomarkers associated with the variability of IL-6 using proteomic analysis. Methods Patients with a diagnosis of SAH, who were admitted to the Department of Neurosurgery within 24 hours after the onset of bleeding were enrolled in this study. All the treatments were standard, including treatment of aneurysm (surgery or endovascular treatment). Additionally, the samples of blood and CSF were collected at intervals of 24 hours from day 1 to day 3 after SAH. IL-6 levels in CSF were evaluated using ELISA in all the samples. Proteomic analyses were performed by liquid chromatography-mass spectrometry using a bottom-up approach with respect to IL-6 levels in CSF. Results This poster summarizes the primary results that characterize SAH-associated proteomic changes in blood and CSF in 29 SAH patients. There are 15 females and 14 males, and the mean age of the study group is 55,03 years. Most patients suffered from mild/moderate SAH (WFNS 1 – 10 patients, 2 – 4 patients, 3 -6 patients, 4 -1 patients, 5- 8 patients). Seven patients underwent surgical treatment, four patients were treated by endovascular procedures, and the source of bleeding was not proven in two cases. The preliminary results indicate the upregulation of processes related to inflammation, apoptosis, and coagulation. Several candidate proteins including IG heavy chain protein, Phosphatidylinositol-glycan-specific phospholipase D, EGF containing fibulin extracellular matrix protein 1 or Coagulation factor 11 protein will be the subject of further research concerning IL-6 expression. Conclusions Processes related to inflammation, apoptosis and coagulation cascade are promising candidates for research of pathophysiology of SAH. Deeper understanding of these processes may lead to identification of new diagnostic markers, which may be useful in treatment of SAH patients.

Návaznosti

LM2023042, projekt VaV

Název: Česká infrastruktura pro integrativní strukturní biologii

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CIISB - Česká infrastruktura pro integrativní strukturní biologii

NU23-04-00382, projekt VaV

Název: Proteomická identifikace biomarkerů asociovaných s variabilitou IL-6 u aneurysmálního subarachnoidálního krvácení

Investor: Ministerstvo zdravotnictví ČR, Proteomická identifikace biomarkerů asociovaných s variabilitou IL-6 u aneurysmálního subarachnoidálního krvácení, Podprogram 1 - standardní

90254, velká výzkumná infrastruktura

Název: e-INFRA CZ II

Citovat

SMRČKA, Martin; Ondřej NAVRÁTIL; Jolana LIPKOVÁ; Michal JURAJDA; Zbyněk ZDRÁHAL; David POTĚŠIL; Michal KÝR a Kamil ĎURIŠ. Proteomic profiles of patients suffering from subarachnoid hemorrhage. In EANS2025 Vienna Congress. 2025.

@proceedings{2535513,
   author = {Smrčka, Martin and Navrátil, Ondřej and Lipková, Jolana and Jurajda, Michal and Zdráhal, Zbyněk and Potěšil, David and Kýr, Michal and Ďuriš, Kamil},
   booktitle = {EANS2025 Vienna Congress},
   keywords = {subarachnoid hemorrhage; IL-6; inflammation; proteomics; biomarkers},
   language = {eng},
   title = {Proteomic profiles of patients suffering from subarachnoid hemorrhage},
   year = {2025}
}

TY  - CONF
ID  - 2535513
AU  - Smrčka, Martin - Navrátil, Ondřej - Lipková, Jolana - Jurajda, Michal - Zdráhal, Zbyněk - Potěšil, David - Kýr, Michal - Ďuriš, Kamil
PY  - 2025
TI  - Proteomic profiles of patients suffering from subarachnoid hemorrhage
KW  - subarachnoid hemorrhage
KW  - IL-6
KW  - inflammation
KW  - proteomics
KW  - biomarkers
N2  - Background Inflammation is an important contributor to early brain injury after subarachnoid hemorrhage (SAH). IL-6 represents the most frequently studied marker of SAH-associated inflammation. However, IL-6 levels after SAH are highly variable, and therefore, it is not possible to define diagnostically relevant threshold levels. Our project aims to identify biomarkers associated with the variability of IL-6 using proteomic analysis. Methods Patients with a diagnosis of SAH, who were admitted to the Department of Neurosurgery within 24 hours after the onset of bleeding were enrolled in this study. All the treatments were standard, including treatment of aneurysm (surgery or endovascular treatment). Additionally, the samples of blood and CSF were collected at intervals of 24 hours from day 1 to day 3 after SAH. IL-6 levels in CSF were evaluated using ELISA in all the samples. Proteomic analyses were performed by liquid chromatography-mass spectrometry using a bottom-up approach with respect to IL-6 levels in CSF. Results This poster summarizes the primary results that characterize SAH-associated proteomic changes in blood and CSF in 29 SAH patients. There are 15 females and 14 males, and the mean age of the study group is 55,03 years. Most patients suffered from mild/moderate SAH (WFNS 1 – 10 patients, 2 – 4 patients, 3 -6 patients, 4 -1 patients, 5- 8 patients). Seven patients underwent surgical treatment, four patients were treated by endovascular procedures, and the source of bleeding was not proven in two cases. The preliminary results indicate the upregulation of processes related to inflammation, apoptosis, and coagulation. Several candidate proteins including IG heavy chain protein, Phosphatidylinositol-glycan-specific phospholipase D, EGF containing fibulin extracellular matrix protein 1 or Coagulation factor 11 protein will be the subject of further research concerning IL-6 expression. Conclusions Processes related to inflammation, apoptosis and coagulation cascade are promising candidates for research of pathophysiology of SAH. Deeper understanding of these processes may lead to identification of new diagnostic markers, which may be useful in treatment of SAH patients.
ER  -

Přehled o publikaci